---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-171148"
form_type: "8-K"
ticker: null
cik: "0001044378"
company_name: "BIOCEPT INC"
filed_at: "2023-06-21T23:59:59+00:00"
generated_at: "2026-06-13T19:40:13.333490+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biocept appoints Antonino Morales as President and CEO; Riccitelli resigns

## Summary
- Samuel D. Riccitelli resigned as Interim President and CEO and from Board, effective June 16, 2023.
- Antonino Morales appointed President and CEO; continues as CFO and Board member.
- Morales' base salary increased from $400K to $470K; target bonus raised from 40% to 50%.
- Robert Walsh promoted to VP, Controller and principal accounting officer.
- Walsh, a CPA, joined Biocept in May 2022; previously at PwC and CFGI.

## SEC filing metadata
- accession: 0001193125-23-171148
- form_type: 8-K
- cik: 0001044378
- company_name: BIOCEPT INC
- filed_at: 2023-06-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1044378/000119312523171148/0001193125-23-171148-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1044378/000119312523171148/d524228d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-171148
- JSON: https://secwatch.observer/filing/0001193125-23-171148.json
- Plain text: https://secwatch.observer/filing/0001193125-23-171148.txt

## Key facts
- Executive change
  Samuel D. Riccitelli resigned as Interim President and Chief Executive Officer at BIOCEPT INC.
  - Action: resigned
  - Role: Interim President and Chief Executive Officer
  source text: On June 16, 2023, Samuel D. Riccitelli resigned from his position as Interim President and Chief Executive Officer of Biocept, Inc. (the “Company”), and from the Company’s Board of Directors (the “Board”), effective June 16, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1044378/000119312523171148/0001193125-23-171148-index.htm
- Executive change
  Robert Walsh changed role as Vice President, Controller and principal accounting officer at BIOCEPT INC.
  - Action: promoted
  - Role: Vice President, Controller and principal accounting officer
  source text: On June 16, 2023, Robert Walsh, the Company’s Controller, was promoted to Vice President, Controller and principal accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1044378/000119312523171148/0001193125-23-171148-index.htm
- Executive change
  Antonino Morales was appointed as President and Chief Executive Officer at BIOCEPT INC.
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On June 16, 2023, the Board appointed Antonino Morales as the Company’s President and Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1044378/000119312523171148/0001193125-23-171148-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.